REFERENCES
- Als-Nielsen, B., W. Chen, C. Gluud, and L. L. Kjaergard. 2003. Association of funding and conclusions in randomized drug trials. JAMA 290 (7):921–8. doi:https://doi.org/10.1001/jama.290.7.921.
- DuBois, J. M., E. M. Kraus, A. Mikulec, S. Cruz, and E. Bakanas. 2013. A humble task: Restoring virtue in an age of conflicted interests. Academic Medicine 88 (7):924–8. doi:https://doi.org/10.1097/ACM.0b013e318294fd5b.
- Fins, J. J., and N. D. Schiff. 2010. Conflicts of interest in deep brain stimulation research and the ethics of transparency. The Journal of Clinical Ethics 21 (2):125–32.
- MacDuffie, K. E., S. Ransom, and E. Klein. 2022. Neuroethics inside and out: A comparative survey of neural device industry representatives and the general public on ethical issues and principles in neurotechnology. AJOB Neuroscience 13 (1):44–54. doi: https://doi.org/10.1080/21507740.2021.1896596.
- McIntosh, T., and J. M. DuBois. 2020. From research to clinical practice: Ethical issues with neurotechnology and industry relationships. AJOB Neuroscience 11 (3):210–2. doi:https://doi.org/10.1080/21507740.2020.1778122.
- National Academies of Sciences Engineering and Medicine. 2017. Fostering Integrity in Research. Washington, DC: The National Academies Press.
- National Institutes of Health. 2021. NIH-Wide Strategic Plan Fiscal Years 2021–2025.
- Porter, T., and P. Miles. 2013. CSR longevity: Evidence from long-term practices in large corporations. Corporate Reputation Review 16 (4):313–40. doi:https://doi.org/10.1057/crr.2013.17.
- Research and Markets. 2018. The Market for Neurotechnology: 2018–2022.
- Schein, E. H. 2010. Organizational culture and leadership. Vol. 4th edition, The Jossey-Bass business & management series. San Francisco, CA: Jossey-Bass.